STAR Ph2 study of BI 1810631 for the treatment of HER-2 mutated solid tumors
Phase II Clinical Trial
Beamion PANTUMOR-1: A Phase II multicentre multicohort open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)